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Background Histamine-2-receptor antagonist (H2RA) is one of the common gastroprotective co-2 
therapies with non-steroidal anti-inflammatory drugs (NSAIDs) for the prevention or treatment of 3 
peptic ulcers (PUs).To date, no study has directly compared the prophylactic effectiveness between 4 
high-dose and low-dose H2RA.  5 
Objective To compare the effectiveness of high-dose versus low-dose H2RAs in the primary 6 
prophylaxis of PUs among short-term NSAID users. 7 
Methods A retrospective cohort study was conducted using the Clinical Data Analysis and 8 
Reporting System (CDARS) in Hong Kong. Patients aged 18 years or above who received a single 9 
prescription of oral NSAID with oral H2RA were identified within the study period (1 January 2009 10 
to 31 December 2012). Patients with a history or risk factors for PU in the corresponding two years 11 
prior to the index date (of the first NSAID prescription) were excluded. Log binomial regression 12 
analysis was used to calculate the relative risk of PU among NSAID users on high-dose-H2RA 13 
versus low-dose-H2RA exposure. 14 
Results Among the NSAID cohort (n=102 042), 77 509 (76%) were on low-dose-H2RA and 24 533 15 
(24%) were on high-dose-H2RA. Of the total 69 PU cases identified during the drug exposure 16 
period, 64 (0.08%) received low-dose-H2RA and 5 (0.02%) received high-dose-H2RA. The overall 17 
absolute risk of PUs for NSAID users whilst on H2RA was approximately 1 per 1 479 patients. The 18 
adjusted relative risk for NSAID users receiving high-dose-H2RA versus low-dose-H2RA was 0.32 19 
(95% Confidence interval 0.13 to 0.79). Patients aged ≥65 years, on longer duration of treatment, or 20 
concomitant use of antiplatelet agents were found to be at higher risk of PU.  21 
Conclusion High-dose-H2RA showed greater effectiveness than low-dose-H2RA in the primary 22 
prophylaxis of NSAID-associated PUs in short-term new-users.  23 
(Word count: 275) 24 
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Key Points: 25 
 The effectiveness of high-dose and low-dose histamine-2 receptor antagonists for the 26 
prevention of peptic ulcers has not been directly compared. 27 
 The absolute risk of peptic ulcer among non-steroidal anti-inflammatory drug new-users 28 
with concurrent use of histamine-2 receptor antagonists was approximately 0.07%, and the 29 
incidence rate was approximately 11.4 per 1000 patient-years. 30 
 High-dose histamine-2 receptor antagonist showed greater effectiveness than its low-dose 31 
form in the primary prophylaxis of NSAID-associated PUs in short-term new-users.   32 
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1. Introduction  33 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed 34 
treatment used for pain relief, fever and rheumatic disorders such as rheumatoid arthritis, 35 
osteoarthritis, acute gout, and other inflammatory pain management [1-3]. However, as NSAIDs 36 
inhibit the production of prostaglandins and increase gastric acid secretion [4], their potential to 37 
cause peptic ulcers (PUs), including gastric and duodenal ulcers, remains a major concern [5]. A 38 
previous study showed that the baseline incidence of hospitalisation with upper gastrointestinal 39 
event in patients receiving NSAIDs was about 2% [6]. In addition, several risk factors for NSAID-40 
associated PUs are well-documented, including prior history of gastrointestinal events, aged 65 41 
years or older, high dose NSAID, and concurrent use of corticosteroids, anticoagulants and 42 
antiplatelet agents [7]. Gastroprotective agents (GPA) such as histamine-2-receptor antagonist 43 
(H2RA), proton pump inhibitor (PPI) and misoprostol are commonly prescribed together with 44 
NSAIDs for the treatment or prevention of PUs [8-12]. 45 
A Cochrane review reported that both standard-dose H2RA (ranitidine 300mg/day or famotidine 46 
40mg/day) and high-dose H2RA (ranitidine 600mg/day or famotidine 80mg/day) were effective 47 
compared with placebo in the prevention of NSAID-associated endoscopic PUs (i.e. peptic mucosal 48 
lesion observed under endoscopy [13]). The relative risk (RR) for standard-dose H2RA was 0.63 49 
(95% Confidence Interval 0.45 to 0.88) and 0.41 (95% CI 0.26 to 0.63) for high-dose H2RA. As the 50 
95% CI overlapped in this indirect comparison, it is unclear whether high-dose H2RA is indeed 51 
more effective. 52 
We were unable to identify any published head-to-head study comparing high-dose versus standard-53 
dose H2RA, as all data were based on indirect comparisons. Therefore, it is difficult to draw 54 
conclusions on the effectiveness of different doses of H2RAs in preventing NSAID-associated PUs. 55 
Most of the clinical trials investigating NSAID-associated PU prophylaxis/treatment included 56 
patients with a previous history of PU, i.e. secondary prophylaxis. For instance, all the patients 57 
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included in Wolde et al’s study had a history of ulcer [14]. Hudson et al’s study included 28% and 58 
31% of patients with previous ulcers in the placebo and H2RA treatment group, respectively [15]. It 59 
is still unclear how effective different doses of H2RA are in primary prophylaxis. Finally, it has 60 
been argued that many endoscopic ulcers may, in fact, be asymptomatic with no clinical symptoms 61 
[13,16, 17], which are different from clinical ulcers (i.e. symptomatic ulcers or ulcer complications).  62 
In addition, Yeomans et al demonstrated the difficulty with using endoscopic PU as an outcome in 63 
that a standard-dose H2RA (ranitidine 300mg/day) group was almost 3.5 times more likely to 64 
develop endoscopic PU than the PPI group. However, Yeomans’ study also reported no difference 65 
between PPI and standard-dose H2RA in preventing clinical PUs [18]. These debates reveal a 66 
“translational evidence gap” in the randomised control trial results and the clinical practice. 67 
Therefore, investigating the effectiveness of different doses of H2RA in preventing NSAID-68 
associated PU in real-life practice becomes an important public health issue in places like Hong 69 
Kong, where H2RAs are the main prophylactic treatment prescribed [19]. 70 
The objective of our study therefore was to investigate the absolute risk and incidence rate of 71 
clinical PUs among NSAID users whilst on H2RA and, to compare the effect of high-dose versus 72 
low-dose H2RA in the primary prophylaxis of NSAID-associated PUs in short-term users.  73 
2. Methods 74 
2.1. Data sources  75 
In this study, we used the Clinical Data Analysis and Reporting System (CDARS), a database 76 
developed by the Hong Kong Hospital Authority (HA). The HA is a statutory body which manages 77 
all publicly-funded hospitals and their ambulatory clinics (primary and specialist out-patient) in 78 
Hong Kong [20]. Prescriptions obtained from HA ambulatory clinics must be dispensed by HA 79 
pharmacies because community pharmacies do not dispense HA prescriptions. As a publicly-funded 80 
primary, secondary and tertiary healthcare provider, the HA’s health service is available to all Hong 81 
Kong residents (over 7 million people) [21].  82 
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In 1995, the HA developed Clinical Management System (CMS). The CMS is a computerised 83 
clinical management system which allows clinicians to order, document and review patient care 84 
through an electronic patient record. Patient data are recorded in CMS by trained clinicians, and 85 
typically include basic demographics, diagnosis, payment method, prescriptions, laboratory tests, 86 
admissions and discharge information, which are directly transferred to CDARS.  Only trained 87 
clinicians are able to prescribe through CMS, where the drug name, dose and frequency are stored. 88 
Prescriptions are forwarded to the corresponding pharmacy department and verified by a registered 89 
pharmacist who dispenses the drugs.  90 
CDARS contains the records of all in-patients and out-patients attending HA clinics and hospitals, 91 
including data transferred from the Accident and Emergency Information System, Medical Record 92 
Abstract System, In-Patient Administration System, Pharmacy Management System/Corporate 93 
Drug Dispensing History. Patient records are anonymised (name, Hong Kong identification card 94 
number, address and telephone number are withheld) to maintain confidentiality. A reference 95 
number is generated to facilitate data retrieval and further analysis. CDARS contains clinical data 96 
from 42 public hospitals and institutions via seven geographic clusters in Hong Kong [22] and has 97 
been used in several high quality epidemiological studies [23-26].   98 
2.2. Study Design 99 
This is a retrospective cohort study to investigate the dose effect of H2RA in NSAID users with 100 
respect to the clinical outcome of PU. 101 
2.3. Patient identification 102 
An inception cohort of patients aged 18 years or above prescribed NSAIDs with H2RA issued by 103 
the ambulatory clinic between 1 January 2009 and 31 December 2012 (study period) was retrieved 104 
from the CDARS database. The NSAIDs and H2RAs included in the HA formulary are shown in 105 
Table 1. We defined the date of the first NSAID prescription during the study period as the index 106 
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date. We specifically selected patients with only one prescription for consistency in the setting of 107 
numerous clinical possibilities including treatment course definition of multiple NSAID 108 
prescriptions and switching between NSAIDs. 109 
2.4. Exclusion criteria  110 
Patients with unknown date of birth, gender, prescription information, or with multiple or non-oral 111 
NSAID prescriptions during the study period were excluded. To obtain a new-user cohort, those 112 
who had received NSAIDs within the screening period (2 years prior to the index date) were 113 
excluded. Further, patients with a previous diagnosis of PU or Helicobacter pylori (H. pylori) 114 
infection, received triple therapy for H.pylori eradication (Table 1) or gastrointestinal endoscopy 115 
procedure during the screening period were also excluded. The International Classification of 116 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes used for identifying diseases 117 
and procedures are listed in Table 2. The flowchart in Figure 1 illustrates patient inclusion and 118 
exclusion.  119 
2.5. Definitions of Exposure 120 
Based on the British National Formulary (63
nd
 edition),[27] high-dose H2RA was defined as 121 
double-dose or higher, and low-dose was defined as lower than double-dose (including standard-122 
dose) (Table 3). The drug exposure period was defined as the prescription period in which patients 123 
were concurrently prescribed NSAID with H2RA. The observation was censored by the end of the 124 
prescription, diagnosis of PU, prescription of another GPA (e.g. PPI, misoprostol), death or end of 125 
study period (31 December 2012), whichever was earliest.  126 
2.6. Outcome 127 
The outcome of interest in this study was PU within the drug exposure period during 2009-2012. 128 
PU diagnoses were identified from the primary diagnostic codes (ICD-9-CM 531, 532, 533 and 534) 129 
(Table 2), including acute or chronic peptic ulcers with or without mention of haemorrhage or 130 
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perforation. Ninety-six percent of the PU cases were confirmed with GI endoscopy, GI surgery or 131 
related diagnostic procedures (Table 2). All PU cases were confirmed with a record of hospital 132 
admission. Only the first episode of PU was counted and observation was censored thereafter.  133 
2.7. Covariates 134 
The commonly reported risk factors for PU were considered in our study as covariates:  age 135 
≥65years; concomitant use of corticosteroids, anticoagulants or antiplatelet agents (Table 1); 136 
NSAID types (ibuprofen, diclofenac, naproxen and others); NSAID doses (low, medium/high) and 137 
duration of NSAID exposure [6, 28]. Based on the British National Formulary (63
nd
 edition) and 138 
existing literature [27, 29, 30], the dose of NSAID was categorised into low and medium/high dose 139 
(Table 3). 140 
2.8. Statistical Analysis 141 
The adjusted RR of PU in NSAID users receiving high-dose versus low-dose-H2RA and 142 
corresponding 95% confidence intervals were estimated using log-binomial regression. The effect 143 
of age, gender and other covariates mentioned previously were also analysed.  144 
The crude absolute risks (AR) and incidence rates (IR) of experiencing PU in comparative groups 145 
and overall patients were calculated based on the following equations: 146 
crude absolute risk (AR)
=
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑒𝑑 𝑤𝑖𝑡ℎ 𝑃𝑈 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 
Total number of patients
 
crude incidence rate (IR) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑒𝑤 𝑃𝑈 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
patient years at risk 𝑤𝑖𝑡ℎ𝑖𝑛 the observation period
 
The Wilson score interval was used to calculate the corresponding 95% confidence interval for the 147 
AR [31]. The 95% confidence interval of IR was calculated based on Rothman and Greenland’s 148 
method [32].  149 
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The number needed to treat (NNT) was calculated to illustrate the observed effect size using the 150 
equation NNT=1/(risk among low-dose-H2RA users with PU − risk among high-dose-H2RA users 151 
with PU) [33].  152 
2.9. Sample size calculation 153 
Kelsey et al’s method was used to calculate the sample size required [34]. Assuming that the 154 
background incidence of hospitalisation with PUs is approximately 2% [6], a minimum sample size 155 
of 6 223 and 18 668 patients in each arm is required respectively, in order to detect a RR of 0.65 156 
comparing high-dose versus low-dose-H2RA (the RR from Rostom et al) [17] with 80% power 157 
(two-sided 95% CI).  158 
2.10. Sensitivity and subgroup analyses   159 
Three sensitivity analyses were performed to test the robustness of the study results. The first 160 
analysis addressed issues around the delayed effect of drug exposure and development of PU, as 161 
well as potential non-compliance scenarios by extending the follow-up period for 30 days. The 162 
second analysis included any PU diagnosis as an outcome instead of restricting them to diagnosis 163 
during hospitalisation, to assess whether the inclusion of out-patient diagnosis would affect the 164 
conclusion. The final sensitivity analysis excluded any PU diagnosis without confirmation with GI 165 
endoscopy, GI surgery or related diagnostic procedures.  166 
Subgroup analysis was also performed to estimate the RR of high-dose versus low-dose H2RA in 167 
three groups of patients separately; elderly patients (aged 65 or above), and patients with longer 168 
treatment duration (30-60 days, or over 60 days). 169 
Data analyses were performed using Statistical Analysis System (SAS) version 9.3 (SAS Inc., 170 
United States). A significance level of 5% was used in all statistical analyses. 171 
3. Results 172 
 11 
 
3.1. Patient characteristics 173 
Between 2009 and 2012, a total of 102 042 patients with a single prescription of oral NSAID with 174 
co-prescription of H2RA met the inclusion criteria (Figure 1). Of these patients, 77 509 (76.0%) 175 
were on low-dose-H2RA (32 751, 42.3% male), and 24 533 (24.0%) were on high-dose-H2RA (10 176 
463, 42.6% male).  177 
Patient characteristics by exposure group of different doses of H2RA are detailed in Table 4. Over 178 
99.9% of patients were prescribed famotidine in clinical practice in Hong Kong. More than 20% of 179 
patients were aged 65 years or older. Over 70% of patients were on medium or high dose NSAID in 180 
both treatment groups. In NSAID users receiving low-dose-H2RA, the most commonly prescribed 181 
oral NSAID were diclofenac, followed by naproxen and ibuprofen; while diclofenac, ibuprofen and 182 
naproxen were the most commonly prescribed NSAID in the high-dose-H2RA group. In both 183 
groups, less than 10% of patients were concurrently prescribed corticosteroids, anticoagulants or 184 
antiplatelet agents respectively. Over 80% of the NSAID prescriptions were of short duration (i.e. 185 
less than 1 month) in both treatment groups, with a mean duration of 23 and 18 days in low-dose-186 
H2RA and high-dose-H2RA groups respectively.  187 
3.2. Crude absolute risks and incidence rates of PU hospitalisation 188 
The ARs and IRs of PU are shown in Table 5. A total of 69 PU cases were identified during drug 189 
exposure in the study cohort, in which 64 patients received low-dose-H2RA and 5 received high-190 
dose-H2RA. The AR of PU whilst on low-dose-H2RA in NSAID users was 0.08% (0.06% to 191 
0.11%), and the AR was 0.02% (0.01% to 0.05%) whilst on high-dose-H2RA. The overall AR of 192 
PU was 0.07% (0.05% to 0.09%), approximately 1 per 1 479 patients.  193 
The IR of PU in NSAID users whilst on low-dose-H2RA was 13.3 per 1000 patient-years (10.4 to 194 
17.0), whereas the IR was 4.1 per 1000 patient-years (1.7 to 9.9) whilst on high-dose-H2RA.  The 195 
overall IR of PU in these NSAID users was 11.4 per 1000 patient-years (9.0 to 14.5).  196 
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3.3. Number needed to treat 197 
The number needed to treat to prevent PUs among NSAID users in Hong Kong would be 1/ [(64/77 198 
509)—(5/24 533)] =1 608, if the estimated effect was seen in a randomised trial. We estimated that 199 
an average of 48 cases of PU could have been prevented if all patients were given high-dose H2RA 200 
during the study period. 201 
3.4. Adjusted relative risk of PU hospitalisation 202 
The adjusted RR of PU comparing high-dose-H2RA versus low-dose-H2RA in NSAID users was 203 
0.32 (0.13 to 0.79), indicating the superior effectiveness of high-dose-H2RA in preventing NSAID-204 
associated PUs in this study population (Table 6).  205 
Patients aged 65 years or above showed a significantly higher risk of experiencing PU with a RR of 206 
11.84 (6.34 to 22.14) compared to those under 65 years old. Moreover, the risk of PU was 207 
significantly higher in patients with longer treatment duration. Compared to short-term treatment 208 
(less than 1 month), the respective RR was 3.94 (2.06 to 7.55) for 30-60 days treatment and 4.76 209 
(2.75 to 8.23) for treatment longer than 2 months. 210 
Patients receiving concurrent antiplatelet agents showed a significantly higher risk of PU than those 211 
who did not, with a RR of 1.85 (1.08 to 3.17). 212 
Our results also demonstrate that female and male patients receiving NSAID plus H2RA showed a 213 
similar risk of PU, with a RR of 0.69 (0.43 to 1.11). In addition, there was no significant difference 214 
in PU risk for patients receiving different doses or types of NSAID. 215 
3.5. Sensitivity and Subgroup analyses  216 
All sensitivity analyses yielded similar results to the main analysis (Table 6). In terms of subgroup 217 
analysis, there were 24 117 patients aged 65 or above, 7 469 patients with 30-60 days of treatment 218 
and 8 469 patients with over 60 days of treatment. Subgroup analysis showed that among elderly 219 
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patients, high-dose-H2RA was able to significantly lower the PU risk compared to low-dose-H2RA, 220 
with a RR of 0.36 (0.15 to 0.91) (Supplementary Table 1). High-dose-H2RA users of longer 221 
duration (30-60 days or over 60 days) were less likely to experience PU than low-dose-H2RA users; 222 
however, the results were not statistically significant.  223 
4. Discussion  224 
4.1. Comparisons with other studies and implications of results 225 
Indirect comparison from the Cochrane meta-analysis shows that high-dose H2RAs are not 226 
significantly more effective than low-dose H2RAs in the prophylaxis of endoscopic PUs [17]. To 227 
our knowledge, our study was the first to demonstrate that the risk of clinical PU was significantly 228 
lower among new NSAID users prescribed with high-dose compared to low-dose-H2RA. H2RAs 229 
suppress both the basal and stimulated acid secretion by blocking histamine type-2 receptors on the 230 
parietal cells, therefore serving as gastroprotective agents commonly used for prophylaxis or 231 
treatment of NSAID associated PU. As an inverse agonist and competitive antagonist of histamine, 232 
the dose-dependent effect of H2RAs may be the reason that high-dose H2RA has higher efficacy 233 
for the prophylaxis of NSAID-associated PU [35-37].  234 
Current guidelines recommend that for patients at high (e.g. prior PU or with more than two 235 
gastrointestinal (GI) risk factors) or moderate risk (one to two GI risk factors) of PU, NSAID plus 236 
misoprostol or PPIs should be used rather than H2RAs [28, 38, 39]. However, Ho et al reported that 237 
of the NSAID users who developed ulcer bleeds while on GPA prophylaxis, approximately 80% 238 
received H2RA rather than PPI in Hong Kong [19]. The choice of H2RA over PPI is likely to be 239 
influenced by the fact that PPI costs up to 30 times more than H2RA in Hong Kong. A 240 
pharmacoeconomics study conducted by Brown et al also concluded that the optimal strategy for 241 
PU prophylaxis in NSAID-users depends on ‘willingness-to-pay’ and co-therapy with H2RAs is the 242 
least costly strategy [40]. Another economic analysis even suggested H2RAs be co-prescribed to all 243 
NSAID users for ulcer prophylaxis, especially among patients with low- to average-PU risk [11]. 244 
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To date, H2RAs are much more commonly prescribed than PPIs in Hong Kong due to cost 245 
constraints, whereas studies report that PPI prescriptions have overtaken that of H2RAs in NSAID 246 
users in other countries such as Australia, Netherlands and Spain [41-43].  247 
However, our results showed that among the NSAID users concurrently receiving H2RAs, 76% 248 
received low-dose-H2RA as primary prophylaxis for PU compared to 24% of patients receiving 249 
high-dose H2RA. This might be of concern for clinical practice in Hong Kong, since high-dose 250 
H2RA should be preferred given the evidence of greater prophylactic effect compared to low-dose 251 
[8]. Although the choice of H2RAs for PU prophylaxis among NSAID users is, to some extent, 252 
reasonable in Hong Kong, high-dose-H2RA should be prescribed over low-dose-H2RA. 253 
The overall AR of PU in users prescribed NSAID with H2RA was 69 per 102 042 patients (0.07%), 254 
which is much lower than that reported in the literature [6, 44]. The most probable explanation for 255 
this low absolute PU risk is due to the “new-user” and “new-patient” design of our study. Since 256 
patients with prior PU, NSAID/GPA exposure, H. pylori infection or previous GI endoscopy 257 
procedures at the screening period were excluded; it is not surprising that PU risks among these new 258 
patients are much lower.  259 
In line with previous studies, our results showed that patients aged 65 or above posed a significantly 260 
higher risk of NSAID-associated PU with a RR of 11.84 (6.34 to 22.14). Further, longer NSAID 261 
treatment duration led to an approximately 3-4 fold higher risk of PU. Subgroup analysis showed 262 
the greater protective effect of high-dose compared to low-dose H2RAs in the elderly subgroup. 263 
High-dose-H2RA users of longer duration (30-60 days or over 60 days) were also less likely to 264 
experience PU than low-dose-H2RA users; however, the results did not reach significance possibly 265 
due to the low number of patients with PU in the subgroup. Nevertheless, these findings highlight 266 
the importance of an appropriate approach to PU prophylaxis in clinical practice among elderly 267 
NSAID users. Shorter NSAID treatment duration is preferred and high-dose H2RAs should be used 268 
for PU prophylaxis.  269 
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Previous studies and guidelines have stated that concurrent use of corticosteroids, anticoagulants or 270 
antiplatelet agents are well-established risk factors for NSAID-associated GI events [28, 45-47]. 271 
Our results show that concomitant use of antiplatelet agents resulted in a higher risk of clinical PU 272 
among NSAID users despite the dosage of H2RA. However, there was no significant difference in 273 
PU risk between patients with and without concurrent treatment of corticosteroids or anticoagulants. 274 
The study is not adequately powered to detect the difference possibly due to the scant number of PU 275 
cases and small proportion of concomitant use of these drugs (less than 10% respectively) among 276 
these new-users of NSAID plus H2RA. 277 
MacDonald et al reported that patients receiving medium or high dose NSAID had a higher risk of 278 
developing complicated GI events, with RRs of 1.41 (1.03 to 1.93) and 1.92 (1.18 to 3.14) 279 
respectively. However, medium or high dose NSAIDs posed similar risks for overall GI events 280 
compared to low dose NSAIDs, with RRs of 1.25 (0.98 to 1.58) and 1.39 (0.93 to 2.07) [6]. From 281 
our findings, a slight tendency was also shown towards a non-significant higher risk of PU in 282 
patients receiving medium/high dose NSAIDs, with a RR of 1.05 (0.37 to 2.94). In addition, 283 
MacDonald et al showed that compared to ibuprofen, the RR of upper GI adverse event was 1.35 284 
(0.69 to 2.62) among diclofenac users and 1.44 (0.92 to 2.45) among naproxen users [6]. Our results 285 
also demonstrated that diclofenac and naproxen had a statistically non-significant higher PU risk 286 
compared to ibuprofen.  287 
4.2. Strengths and limitations of study 288 
To our knowledge, this is the first pharmacoepidemiological study comparing high-dose versus 289 
low-dose H2RA in the prophylaxis of NSAID-associated PU. One major advantage of our study is 290 
that the diagnosis of PU was identified by ICD-9-CM diagnostic codes as an outcome rather than 291 
endoscopic PU commonly used in clinical trials.  Therefore, our study adds significant knowledge 292 
to the role of H2RA in the prophylaxis of NSAID-associated PU in real life practice. Further, we 293 
chose the “new-user” [48] and “new-patient” study design, which focused on the primary 294 
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prophylaxis of PU in patients with no previous drug exposures or PU history. This allowed us to 295 
specifically investigate new-users with low risk of PU, contributing important knowledge to guide 296 
current practice. By applying the new-user design, as all subjects enter the study at the same time 297 
with no previous drug exposures or outcomes,  “survival bias” is avoided, providing a more 298 
accurate estimation of risk [48].  299 
Several limitations should be acknowledged. Similar to databases from clinical healthcare 300 
management systems in Europe, such as the Clinical Practice Research Datalink (CPRD, previously 301 
known as the General Practice Research Database, GPRD)[49], CDARS does not include over-the-302 
counter (OTC) medicines and data from private healthcare providers. This might have led to a 303 
potential underestimate of NSAID or GPA use among the study population. However, as the Hong 304 
Kong Hospital Authority provides territory-wide healthcare, which is available to all residents, the 305 
impact of missing private or OTC prescriptions is likely to be minimal [50]. Similar to other 306 
pharmacoepidemiological studies using databases, since we used the prescription record as a 307 
reflection of drug exposure, non-adherence cannot be directly addressed. However, we addressed 308 
this issue using sensitivity analysis and our conclusions are robust. There is a possibility that 309 
patients who were “perceived” to be at higher PU risk might have been prescribed high-dose H2RA. 310 
Therefore, our study might be biased against high-dose H2RA and underestimated its protective 311 
effects. Finally, we focused on a group of short-term users who received a single prescription for 312 
NSAID, thus our findings may not be generalised to other patients groups, such as those on long-313 
term NSAID treatment. Further investigation involving patients with multiple NSAID prescriptions 314 
for long-term conditions/treatment using propensity score could be conducted to evaluate different 315 
patient groups.  316 
5. Conclusion 317 
High-dose H2RA showed greater effectiveness compared to low-dose H2RA in the primary 318 
prophylaxis of PU in short-term new-users of NSAIDs. The co-prescribing rate of low-dose H2RA 319 
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was 3-fold that of high-dose H2RA for the primary prophylaxis of NSAID-associated PUs in Hong 320 
Kong, and such practice should be discouraged.   321 
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Table 1. List of drugs included in this cohort study 469 
Drug classification List of drugs 
NSAID 
Diclofenac, ibuprofen, indomethacin, mefenamic acid, naproxen, piroxicam, 
sulindac    
H2RA Ranitidine, famotidine, cimetidine 
PPI Pantoprazole, lansoprazole, esomeprazole, omeprazole, rabeprazole  
Other GPA 
Misoprostol, sucralfate, tripotassium dicitrato bismuthate, bismuth subcitrate, 
bismuth subnitrate, bismuth carbonate, bismuth + iodoform 
Triple therapy 
Pantoprazole/lansoprazole/esomeprazole/omeprazole/rabeprazole/ranitidine(bis
muth) + amoxicillin + clarithromycin 
Corticosteroid 
Betamethasone, dexamethasone, fludrocortisone, hydrocortisone, 
methylprednisolone, prednisolone, triamcinolone acetonide  
Anticoagulant 
Enoxaparin, heparin, nadroparin, protamine sulphate, tinzaparin, warfarin, 
dabigatran 
Antiplatelet agent 
Aspirin, aspirin+glycine, dipyridamole, abciximab, clopidogrel, eptifibatide, 
prasugrel, aggrenox, ticlopidine 
GPA gastroprotective agent, H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-inflammatory drug, 
PPI proton pump inhibitor 
  470 
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Table 2. ICD-9-CM codes for peptic ulcers, gastrointestinal procedures, and Helicobacter 471 
pylori infection 472 
ICD-9-CM codes for PUs 
 531 gastric ulcer (531.0-531.9) 
 532 duodenal ulcer (532.0-532.9) 
 533 peptic ulcer, site unspecified (533.0-533.9) 
 534 gastrojejunal ulcer (534.0-534.9) 
ICD-9-CM codes for gastrointestinal procedures 
 44.1 diagnostic procedures on stomach (44.11-44.19) 
 45.1 diagnostic procedures on small intestine (45.11-45.19) 
 44.4 control of haemorrhage and suture of ulcer of stomach or duodenum 
 87.62 upper GI series 
 88.01 computerized axial tomography of abdomen 
 88.02 other abdomen tomography 
ICD-9-CM codes for H. Pylori infection 
 041.86 H. pylori 
GI gastrointestinal, ICD-9-CM international classification of diseases, ninth revision, Clinical modification, PU peptic 473 
ulcer  474 
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Table 3. Dose classification of NSAIDs and H2RAs 475 
H2RA Low dose  High dose  
ranitidine <600 ≥ 600 
famotidine <80 ≥ 80 
cimetidine <1,600 ≥ 1,600 
NSAID  Medium/High dose 
diclofenac <75 ≥75 
ibuprofen <1,200 ≥1,200 
indomethacin <75 ≥75 
mefenamic acid <1,500 ≥1,500 
naproxen <500 ≥500 
piroxicam <10 ≥10 
sulindac <300 ≥300 
Doses are presented in mg/day  476 
H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-inflammatory drug  477 
 24 
 
Table 4. Patient characteristics by exposure classified according to histamine-2 receptor 478 
antagonist dose 479 
 NSAID+low-dose-H2RA NSAID+high-dose-H2RA 
Total  77,509 24,533 
H2RA type 
Famotidine 77,484 (99.97) 24,532 (100) 
Ranitidine 25 (0.03) 1 (0) 
Sex 
Male 32,751 (42.3) 10,463 (42.6) 
Female 44,758 (57.7) 14,070 (57.4) 
Age in years Mean (SD) 54 (16.5) 52 (16.4) 
Age category 
(years) 
< 65  58,507 (75.5) 19,418 (79.2) 
≥ 65  19,002 (24.5) 5,115 (20.8) 
NSAID dose 
Low 20,845 (26.9) 7,105 (29.0) 
Medium or high 56,664 (73.1) 17,428 (71.0) 
NSAID type 
Ibuprofen 15,181 (19.6) 5,644 (23.0) 
Diclofenac 41,193 (53.1) 14,198 (57.9) 
Naproxen 15,941(20.6) 3,240 (13.2) 
Others 
a
 5,194 (6.7) 1,451 (5.9) 
Concomitant 
drugs 
Corticosteroid 2,617 (3.4)  716 (2.9) 
Anticoagulant 7,223 (9.3) 2,036 (8.3)  
Antiplatelet agent 5,568 (7.2) 1,395 (5.7) 
Treatment  
duration (days) 




< 30  64,509 (83.2) 21,595 (88.0) 
30-60  6,072 (7.8) 1,397 (5.7) 
> 60  6,928 (8.9) 1,541 (6.3) 
Data are presented as n (%) unless otherwise indicated 480 
H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-inflammatory drug, SD standard deviation 481 
a 
Others: indomethacin, mefenamic acid, piroxicam, and sulindac   482 
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Table 5. Absolute risks and incident rates of peptic ulcer hospitalization in users of non-483 
steroidal anti-inflammatory drug + histamine-2 receptor antagonist 484 
 Low-dose-H2RA High-dose-H2RA Total 
Number of patients  77,509 24,533 102,042 
Number of incident PU 
cases  
64 5 69 
Absolute risk  
(%, 95%CI) 
0.08 (0.06–0.11) 0.02 (0.01–0.05) 0.07 (0.05–0.09) 
Total patient-years 
covered 
4,819 1,214 6,034 
Incidence rate  
per 1000  
patient-years (95%CI) 
13.3 (10.4–17.0) 4.1 (1.7–9.9) 11.4 (9.0–14.5) 
CI confidence interval, H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-inflammatory drug, PU peptic 485 
ulcer   486 
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Table 6. Model details of the risk of peptic ulcer in users of non-steroidal anti-inflammatory 487 
drug + histamine-2 receptor antagonist 488 
 Adjusted RR 
a
 (95% CI) P-value 
H2RA dose 
Low 1.00 - 





Low 1.00 - 





Low 1.00 - 





Low 1.00 - 
High 0.33 (0.13–0.83) 0.019 
Sex 
Male 1.00 - 
Female 0.69 (0.43–1.11) 0.125 
Age 
< 65 years 1.00 - 
≥ 65 years 11.84 (6.34–22.14) <.0001 
NSAID dose 
Low 1.00 - 
Medium or high 1.05 (0.37–2.94) 0.927 
NSAID type 
Ibuprofen 1.00  
Diclofenac 3.41 (0.83–14.00) 0.088 
Naproxen 2.71 (0.60–12.25) 0.196 
Others 
e
 2.60 (0.61–11.16) 0.199 
Concomitant 
drugs 
No 1.00 - 
Corticosteroid 1.41 (0.57–3.51) 0.460 
Anticoagulant 0.93 (0.43–2.04) 0.866 





< 30 days 1.00  
30-60 days 3.94 (2.06–7.55) <.0001 
> 60 days 4.76 (2.75–8.23) <.0001 
CI confidence interval, GI gastrointestinal, H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-489 
inflammatory drug, PU peptic ulcer, RR relative risk  490 
a Estimates adjusted for age; sex; NSAID dose; NSAID type; concomitant use of corticosteroid, anticoagulant, or antiplatelet agent; 491 
treatment 492 
duration 493 
b The follow-up period was extended for 30 days 494 
c Any PU diagnosis was included as an outcome instead of restricting them to diagnosis during hospitalization 495 
d Any PU diagnosis without confirmation with GI endoscopy, GI surgery, or related diagnostic procedures was excluded 496 





Figure 1. Illustration of patient inclusion/exclusion 500 
GPA gastroprotective agent, H. Pylori Helicobacter pylori, H2RA histamine-2 receptor antagonist, NSAID non-steroidal 501 
anti-inflammatory drug, PPI proton pump inhibitor, PU peptic ulcer  502 
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Supplementary Table 1.  Subgroup analysis of the risk of peptic ulcer in users of non-steroidal 503 
anti-inflammatory drug+ histamine-2 receptor antagonist 504 
Subgroups 
PU case/Patient number Unadjusted RR 
(95% CI)  




Age ≥ 65 years 5 / 5,115 51 / 19,002 0.36 (0.15–0.91) 0.022 
30-60 days treatment 1 / 1,397 12 / 6,072 0.36 (0.05–2.78) 0.484 
> 60 days treatment 2 / 1,541 21 / 6,928 0.43 (0.10–1.82) 0.413 
CI confidence interval, H2RA histamine-2 receptor antagonist, NSAID non-steroidal anti-inflammatory drugs, PU peptic 505 
ulcer, RR relative risk 506 
